International panel announces new treatment guidelines for HIV

January 18, 2000

An international group of AIDS specialists today (Jan. 19, 2000) released updated guidelines for treating HIV disease in adults. The new guidelines take into account the availability of new anti-retroviral drugs and expanded therapy choices.

Reported in the January 19, 2000, issue of The Journal of the American Medical Association, the recommendations represent the consensus of a 17-member physician panel of the International AIDS Society-USA. That panel was first convened in 1995 to develop treatment guidelines for health care providers that would set a standard of care for HIV. Since then, the panel has reviewed the recommendations annually; a revised version was last issued in July 1998.

The most important changes in the new recommendations are:"In the mid-90s, emerging clinical and basic science data supported a theoretical case for HIV eradication within two to three years through early and aggressive anti-retroviral drug therapy that would completely suppress viral replication," said Paul Volberding, M.D., chair of the IAS-USA board and a University of California-San Francisco professor of medicine. "Now we know that eradication with drug therapy alone is not a realistic goal at this time. Our new recommendations take this into consideration along with long-term survival." Volberding is senior author of the JAMA paper and also serves as director of the UCSF Positive Health Program at San Francisco General Hospital Medical Center.

"Since our last recommendations in 1998 were announced, three effective new drugs have become available and new ways of combining drugs are in common use, greatly increasing the opportunity for positive treatment outcomes in our patients," said Charles C. J. Carpenter, M.D., chair of the panel, first author of the JAMA paper and professor of medicine at the Brown University School of Medicine. "Now with more convenient drug administration schedules and carefully individualized treatment plans, most patients with HIV infection can live fully active and productive lives."

The new guidelines are limited to therapies approved by the U.S. Food and Drug Administration and available in 1999, according to Volberding. Other highlights of the treatment recommendations include:

When to initiate anti-retroviral therapy

Physicians and patients must weigh the risks and benefits of starting therapy and make individual informed decisions. When to initiate therapy and what regimen to choose are crucial decisions, otherwise future options may be severely compromised. Ultimate long-term success may be a function of the aggregate effectiveness of sequential therapies, the panel noted.

Therapy is generally recommended for patients with a confirmed plasma HIV RNA level (viral load) above 30,000 copies per milliliter, irrespective of CD4 cell count, and for patients with CD4 cell counts below 350, irrespective of HIV RNA level.

Initial therapy

Recommendations for specific combination of drugs cannot be made. Choice of a regimen should be individualized based on its potency, tolerability and adverse effects.

Dual protease inhibitor combinations are increasingly being used because they offer pharmacologic and adherence benefits and improved efficacy. Data has shown ritonavir can be used effectively with saquinavir, indinavir, and amprenavir. Also, much more data support the initial use of non-nucleoside RTIs in place of protease inhibitors. These combinations, regardless of the specific class of drug used, can offer potential for increased potency, reduced pill burden, dose frequency and cost, and no mealtime restrictions.

Monitoring therapy

Both CD4 cell and HIV RNA levels are important for evaluating treatment response. The HIV RNA levels should decrease rapidly after therapy is initiated. Failure to achieve a target level of less than 50 copies per milliliter after about 16 to 24 weeks should raise concern about poor adherence, inadequate drug absorption or drug resistance. Increases in CD4 cell counts reflect reconstitution of the immune system.

Changing therapy /regimen

A decision to change therapy must be balanced by consideration of the likelihood that another regimen will achieve control of viral replication or be better tolerated. The panel also pointed out, however, that there is little direct experience with comparative retroviral drug potency, even within drug classes. Changes in a successful regimen should be approached cautiously.

Stopping therapy

Based on clinical and immunologic benefit in patients with advanced disease and few or no remaining anti-retroviral options, it is reasonable to continue treatment as long as possible.

IAS-USA is a national not-for-profit organization based in San Francisco that provides information and educa-tion for physicians involved in HIV/AIDS care. IAS-USA is not affiliated with the worldwide IAS, based in Sweden.
-end-
The panel for the newly released guidelines, in addition to Volberding and Carpenter, included David A. Cooper, M.D., D.Sc., University of New South Wales; Margaret A. Fischl, M.D., University of Miami; Jose M. Gatell, M.D., Ph.D., University of Barcelona; Brian G. Gazzard, M.A., M.D., Chelsea and Westminster Hospital, London; Scott Hammer, M.D., Columbia University; Martin S. Hirsch, M.D., Harvard Medical School; Donna M. Jacobsen, B.S., IAS-USA; and David A. Katzenstein, M.D., Stanford University; Julio S. G. Montaner, M.D., St. Paul's Hospital, Vancouver; Douglas D. Richman, M.D., University of California-San Diego; Michael S. Saag, M.D., University of Alabama-Birmingham; Mauro Schechter, M.D., Ph.D., Universidado Federal do Rio de Janeiro; Robert T. Schooley, M.D., University of Colorado; Melanie A. Thompson, M.D., AIDS Research Consortium of Atlanta; Stefano Vella, M.D., Instituto Superiore de Sanita, Rome; and Patrick G. Yeni, M.D., Hopital Bichat-Claude Bernard X. Bichat Medical School, Paris.

Brown University

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.